Genomics and Precision Public Health Training Course

Dr. Korf is the Associate Dean for Genomic Medicine, School of Medicine; Chief Genomics Officer, UAB Medicine; Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics, Professor of Genetics, Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine, Associate Director for Rare Diseases, Hugh Kaul Personalized Medicine Institute and editor-in-chief of the American Journal of Human Genetics. Dr. Korf is past president of the Association of Professors of Human and Medical Genetics, past president of the American College of Medical Genetics and Genomics, and current president of the ACMG Foundation for Genetic and Genomic Medicine. He has served on the Board of Scientific Counselors of the National Cancer Institute and the National Human Genome Research Institute at the NIH. His major research interests are genomic medicine and the natural history, genetics, and treatment of neurofibromatosis. He serves as principal investigator of the Department of Defense funded Neurofibromatosis Clinical Trials Consortium, and co-PI of the Alabama Genomic Health Initiative and the All of Us Southern Network. He is co-author of Human Genetics and Genomics (medical student textbook, now in fourth edition), and Emery and Rimoin’s Principles and Practice of Medical Genetics.

Stuart K. Shapira, MD, PhD is Associate Director for Science and Chief Medical Officer for the National Center on Birth Defects and Developmental Disabilities at the Centers for Disease Control and Prevention. Dr. Shapira received his PhD degree in Genetics and his MD degree, both from the University of Chicago. He completed a residency in Pediatrics and a clinical fellowship in Genetics and Metabolism at Boston Children’s Hospital. He also completed dual research fellowships in Genetics and Metabolism, and in Allergy and Immunology at Harvard Medical School. Dr. Shapira is board-certified in Clinical Genetics, Biochemical Genetics, and Molecular Genetics. Prior to joining the National Center on Birth Defects and Developmental Disabilities in 2005, Dr. Shapira practiced clinical genetics and metabolic genetics at Baylor College of Medicine in Houston and at the University of Texas Health Science Center in San Antonio.

Dr. Shapira currently serves as chairman of the Dysmorphology Workgroup for the Centers for Autism and Developmental Disabilities Research and Epidemiology and the CDC alternate representative to the Interagency Autism Coordinating Committee and the Federal Agency Workgroup on Autism. His research activities include dysmorphology of autism, birth defects epidemiology, and newborn screening. Dr. Shapira has authored and coauthored more than 100 journal articles, book chapters, and abstracts, and he has been an invited speaker at numerous regional, national, and international scientific conferences.

Dr. Matthew Maenner is an epidemiologist and Chief of the Child Development and Disability Branch at the National Center on Birth Defects and Developmental Disabilities. Prior to this role, he led CDC’s Autism and Developmental Disabilities Monitoring Network, which tracks the prevalence of autism among children, progress in early identification, and needs of adolescents in multiple U.S. communities. Dr. Maenner received the Presidential Early Career Award in Science and Engineering for advancing developmental disabilities research and surveillance. He joined CDC in 2013 as an Epidemic Intelligence Service Officer assigned to the Developmental Disabilities Branch. He received a PhD in Population Health at the University of Wisconsin and completed a postdoctoral fellowship at the Waisman Center, University of Wisconsin-Madison, focused on intellectual and developmental disabilities research.

Sheri Schully, Ph.D., is the deputy chief medical and scientific officer and the lead for ancillary studies in the All of Us Research Program at the National Institutes of Health. Through her leadership, she is establishing ancillary studies as a core and scalable capability of the program that will expand the cohort and deliver new phenotypic, lifestyle, environmental, and biological data to the All of Us Researcher Workbench. Dr. Schully has been involved with shaping the program and setting the scientific vision and strategy since its inception.

Prior to this role, she was a team lead and senior advisor for disease prevention in the Office of Disease Prevention (ODP). There, she led the effort to systematically monitor NIH investments in prevention research and assess the progress of that research. She also served as the team lead for the Knowledge Integration Team as well as a program officer in the Epidemiology and Genomics Research Program at the National Cancer Institute (NCI).  She came to the NIH as an NCI-designated Presidential Management Fellow in 2005.

Dr. Schully's research interests include genomics, personalized medicine, and the integration of genetic and genomic information into clinical and public health practices. Her work has been published in numerous high-impact scientific journals. She earned both a Ph.D. in biological sciences with a concentration in population genetics and a B.S. in zoology with a minor in chemistry from Louisiana State University.

Scott Grosse is senior health economist in the Office of the Director of the National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia, where he has worked since earning his PhD in public health from the University of Michigan in 1996. He conducts health services research, economic evaluations, and policy analyses on rare disorders and neurodevelopmental conditions and associated risk factors. He has 25 years’ experience assessing the utility and cost-effectiveness of genetic testing approaches. He has coauthored more than 250 journal articles.

Dr. Haga is a Professor at Duke University School of Medicine, Department of Medicine, Division of General Internal Medicine, and the Program in Precision Medicine. She has secondary appointments in the Sanford School of Public Policy and the Department of Biology at Duke University, She oversees several education programs for in genetics and genome sciences and regularly teaches undergraduate courses in genomics, bioethics, and pharmacogenetics. Her research interests focus on issues affecting the translation of genomics to clinical practice, particularly in the field of pharmacogenetic testing, and exploring barriers and facilitators to test utilization.

Megan Roberts, Ph.D., is an assistant professor in the Division of Pharmaceutical Outcomes and Policy and the Director of Implementation Science in Precision Health and Society at the UNC Eshelman School of Pharmacy. Her research focuses on evaluating and improving the implementation of genomic medicine. In particular, she is interested in conducting research to understand how precision medicine technologies can be implemented to improve access to and reduce disparities in high-quality care and prevention. To date, her research has largely focused on the intersection between genomic medicine, health equity and implementation science including research about the implementation of population genetic screening, cascade screening for hereditary conditions, precision diagnostics in low resourced settings both globally and in the US, and building capacity for precision public health.

Dr. Mike Murray joined the Icahn School of Medicine at Mount Sinai in 2023, as Chief of the Division of Genomic Medicine and Clinical Director of the Institute for Genomic Health.  He also currently serves as co-chair of the American College of Medical Genetics and Genomics’ Workgroup on Population Screening. 

In 2019 he led the launch of “Yale Generations”, a health system based genomic health project that links genomic data with electronic health data in order to enable both research and patient care delivery.  From 2013 to 2018 he was the Geisinger Health System’s first director of clinical genomics. At Geisinger he led the design and implementation of the GenomeFIRST program in 2015.  Prior to his time at Geisinger he was on the faculty at Harvard Medical School and was the clinical chief of genetics at Brigham and Women’s Hospital in Boston for nine years. 

He is a physician and is board certified in Internal Medicine and Medical Genetics.  He currently serves as a member of the Board of Directors for the American College of Medical Genetics (ACMG).

Emily Drzymalla received a MPH from Emory University and she has been an ORISE fellow with the Office of Genomics and Precision Public Health for about two and a half years. She has an interest in epigenetics and neuropsychiatric conditions.